BlueBird Bio (Cambridge, MA) a clinical-stage developer of innovative stem cell-based gene therapies for severe genetic disorders, closed a $30M Series C financing. Participants include Arch Venture Partners, Third Rock Ventures, TVM Capital, Forbion Capital Partners and Easton Capital Investment Group.